Items Tagged ‘dnx-2401’

September 19th, 2014

DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial

By

DNAtrix, Inc., experts in oncolytic virus development, today announced that the first patient was treated with the company’s lead product, DNX-2401, a replication competent adenovirus plus gamma interferon in a randomized, multicenter, open-label Phase Ib study for patients with recurrent glioblastoma. “DNAtrix, in collaboration with leading neurosurgeons and neuro-oncologists in the US, is pleased to […]

View full entry

Tags: adenovirus, Brain Cancer, dnx-2401, gamma interferon, gbm, General Brain Cancer, glioblastoma, News, recurrent glioblastoma